Rulings (7)
  • REVIV UK Ltd t/a REVIV

    • Upheld
    • 20 December 2023

    The website for REVIV UK, www.revivme.com/london, seen 1 April 2019, stated on the main page for its London clinic “REVIV IV infusion therapies deliver hydration, vitamins, and antioxidants helping to optimise vital hydration balance and maximise your wellness & efficiency. Whether looking to boost your immun...

  • Chengyi Daily Department Store t/a Shop1102829235 Store

    • Upheld
    • Website (paid ad)
    • 01 November 2023

    A paid-for ad on AliExpress was irresponsible for featuring a model that appeared unhealthily thin and made medicinal claims for an unlicensed product.

  • Dr Rani Ltd t/a Daily Chemist

    • Upheld
    • Search (paid)
    • 01 November 2023

    A paid-for search ad promoted asthma inhalers, which are prescription-only medicines, to the general public.

  • Essential Sounds Hearing

    • Upheld
    • Internet (website content)
    • 01 November 2023

    A website for hearing aids misleadingly stated their products were invisible in the ear, did not provide a refund within the advertised thirty days and made a misleading claim about stock availability.

  • Shenzhen Guangming District Kangshuo E-Commerce Firm t/a Health Support Store

    • Upheld
    • Website (paid ad)
    • 01 November 2023

    A paid-for ad on AliExpress was irresponsible for featuring a model that appeared unhealthily thin and made medicinal claims for an unlicensed product.

  • Nexusbird Inc t/a Motion

    • Upheld
    • Social media (paid ad)
    • 18 October 2023

    A paid-for Facebook ad for an AI-powered calendar made medical claims for a device that had not been registered for those claims, and discouraged essential treatment for ADHD, a condition where medical supervision should be sought.

  • Bronte Ryan t/a Birmingham Aesthetics, bee_enhanced

    • Upheld
    • Social media (own site)
    • 13 September 2023

    An Instagram post by an Aesthetic clinic breached our rules by advertising a prescription-only medicine (POM) to the public.